Skip to main content

Gilead Sciences Inc. (GILD) Stock

Gilead Sciences Inc. Stock Details, Movements and Public Alerts

Stock Details

Gilead Sciences Inc. (GILD), a prominent company in the life sciences sector within the biological products, (no disgnostic substances) industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $116.20. Over the past 52 weeks, it has ranged between $70.17 and $118.28. This places the current price at 98.2% of its 52-week high and 65.6% above its 52-week low. Recent trading volume was recorded at 7,677,168. The International Securities Identification Number (ISIN) for this stock is US3755581036.

Market Cap

$137.67B

52-Week High

$118.28

-1.76% from high

52-Week Low

$70.17

+65.60% from low

Avg Daily Volume

7,677,168

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

23.25

Near market average

Forward P/E

13.99

Earnings expected to grow

PEG Ratio

0.23

Potentially undervalued

Price to Book

7.18

EV/EBITDA

14.62

EPS (TTM)

$4.76

Price to Sales

4.79

Beta

0.31

Less volatile than market

How is GILD valued relative to its earnings and growth?
Gilead Sciences Inc. trades at a P/E ratio of 23.25, which is near the market average of approximately 20, suggesting the market views it as fairly valued relative to its earnings. Looking ahead, the forward P/E of 13.99 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 0.23 suggests the stock may be undervalued relative to its growth rate.
What is GILD's risk profile compared to the market?
With a beta of 0.31, Gilead Sciences Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 7.18 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

20.80%

Operating Margin

38.50%

Return on Equity

32.70%

Return on Assets

12.10%

Revenue Growth (YoY)

-0.30%

Earnings Growth (YoY)

24.80%

How profitable and efficient is GILD's business model?
Gilead Sciences Inc. achieves a profit margin of 20.80%, meaning it retains $20.80 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 38.50% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 32.70% and ROA at 12.10%, the company generates strong returns on invested capital.
What are GILD's recent growth trends?
Gilead Sciences Inc.'s revenue declined by 0.30% year-over-year, indicating challenges in maintaining sales momentum. This contraction may reflect market headwinds, competitive pressures, or strategic transitions. Earnings increased by 24.80% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry averages for proper context.

Dividend Information

Dividend Per Share

$3.10

Dividend Yield

2.86%

Ex-Dividend Date

6/13/2025

Dividend Date

6/27/2025

What dividend income can investors expect from GILD?
Gilead Sciences Inc. offers a dividend yield of 2.86%, paying $3.10 per share annually. This above-average yield of 2-4% provides meaningful income while still allowing the company to reinvest for growth. It compares favorably to the S&P 500 average and offers competitive returns versus bonds in the current rate environment. To receive the next dividend, shares must be purchased before the ex-dividend date of 6/13/2025.
How reliable is GILD's dividend for long-term investors?
The dividend sustainability can be assessed through the payout ratio - Gilead Sciences Inc. pays $3.10 per share in dividends against earnings of $4.76 per share, resulting in a payout ratio of 65.13%. This high payout ratio of 60-90% leaves limited earnings for reinvestment. While currently sustainable, there's less buffer for dividend growth or protection during earnings downturns. The next dividend payment is scheduled for 6/27/2025.

Company Size & Market

Shares Outstanding

1.24B

Book Value/Share

$15.39

Asset Type

Common Stock

What is GILD's market capitalization and position?
Gilead Sciences Inc. has a market capitalization of $137.67B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 1.24B shares outstanding, the company's ownership is widely distributed. As a major player in the BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry, it competes with other firms in this sector.
How does GILD's price compare to its book value?
Gilead Sciences Inc.'s book value per share is $15.39, while the current stock price is $116.20, resulting in a price-to-book (P/B) ratio of 7.55. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$116.77

0.49% upside potential

Analyst Recommendations

Strong Buy

4

Buy

15

Hold

11

Sell

0

Strong Sell

0

How reliable are analyst predictions for GILD?
30 analysts cover GILD with 63% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $116.77 implies 0.5% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on GILD?
Current analyst recommendations:4 Strong Buy, 15 Buy, 11 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jul 1, 2025, 02:35 AM

Technical Indicators

What does GILD's RSI value tell investors?
RSI data is not available for this stock.
How should traders interpret GILD's MACD and moving average crossovers?
MACD and moving average data are not available for this stock.

No technical indicators available yet.

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for GILD and get notified when the price changes.

Stay Ahead of the Market with Gilead Sciences Inc. Alerts

Set up price alerts for Gilead Sciences Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.